JB Pharma publishes sustainability report for FY 2022-23
JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions
JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions
The company will develop and produce premixes for human nutrition applications
Our collaboration with MediSage to present 'Current Approaches to Uro-Oncology' embodies a crucial stride towards comprehensive cancer care
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
AAT is a substantial socio-economic burden to livestock farmers in Sub-Saharan Africa, affecting and killing millions of cattle every year
Meningitis still affects more than 2.5 million people globally each year
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
Subscribe To Our Newsletter & Stay Updated